{
    "root": "66bc8218-ea99-4c2d-931d-c12a53fd33b8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Olanzapine",
    "value": "20250521",
    "ingredients": [
        {
            "name": "OLANZAPINE",
            "code": "N7U69T4SZR"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "olanzapine atypical antipsychotic indicated : oral formulation : · treatment schizophrenia . ( 1.1 ) · adults : efficacy established three trials patients schizophrenia : two 6-week trials one maintenance trial . ( 14.1 ) · adolescents ( ages 13-17 ) : efficacy established one 6-week trial patients schizophrenia ( 14.1 ) . increased potential ( adolescents compared adults ) weight gain dyslipidemia may lead clinicians consider prescribing drugs first adolescents . ( 1.1 ) · acute treatment manic mixed episodes associated bipolar disorder maintenance treatment bipolar disorder . ( 1.2 ) · adults : efficacy established three trials patients manic mixed episodes bipolar disorder : two 3- 4-week trials one maintenance trial . ( 14.2 ) · adolescents ( ages 13-17 ) : efficacy established one 3-week trial patients manic mixed episodes associated bipolar disorder ( 14.2 ) . increased potential ( adolescents compared adults ) weight gain dyslipidemia may lead clinicians consider prescribing drugs first adolescents . ( 1.2 ) · medication therapy pediatric patients schizophrenia bipolar disorder undertaken thorough diagnostic evaluation careful consideration potential risks . ( 1.3 ) · adjunct valproate lithium treatment manic mixed episodes associated bipolar disorder . ( 1.2 ) · efficacy established two 6-week trials adults ( 14.2 ) . maintenance efficacy systematically evaluated . olanzapine fluoxetine combination : treatment depressive episodes associated bipolar disorder . ( 1.5 ) • efficacy established symbyax ( olanzapine fluoxetine combination ) ; refer product label symbyax . treatment treatment resistant depression . ( 1.6 ) • efficacy established symbyax ( olanzapine fluoxetine combination ) adults ; refer product label symbyax",
    "contraindications": "schizophrenia adults ( 2.1 ) oral : start 5‑10 mg daily ; target : 10 mg/day within several days schizophrenia adolescents ( 2.1 ) oral : start 2.5‑5 mg daily ; target : 10 mg/day bipolar disorder ( manic mixed episodes ) adults ( 2.2 ) oral : start 10 15 mg daily bipolar disorder ( manic mixed episodes ) adolescents ( 2.2 ) oral : start 2.5-5 mg daily ; target : 10 mg/day bipolar disorder ( manic mixed episodes ) lithium valproate adults ( 2.2 ) oral : start 10 mg daily depressive episodes associated bipolar disorder adults ( 2.5 ) oral combination fluoxetine : start 5 mg oral olanzapine 20 mg fluoxetine daily depressive episodes associated bipolar disorder children adolescents ( 2.5 ) oral combination fluoxetine : start 2.5 mg oral olanzapine 20 mg fluoxetine daily treatment resistant depression adults ( 2.6 ) oral combination fluoxetine : start 5 mg oral olanzapine 20 mg fluoxetine daily • lower starting dose recommended debilitated pharmacodynamically sensitive patients patients predisposition hypotensive , potential slowed metabolism . ( 2.1 ) • olanzapine may given without regard meals . ( 2.1 ) olanzapine fluoxetine combination : • adjustments , indicated , made individual components according efficacy tolerability . ( 2.5 , 2.6 ) • olanzapine monotherapy indicated treatment depressive episodes associated bipolar disorder treatment resistant depression . ( 2.5 , 2.6 ) • safety co-administration doses 18 mg olanzapine 75 mg fluoxetine evaluated adults . ( 2.5 , 2.6 ) • safety co-administration doses 12 mg olanzapine 50 mg fluoxetine evaluated children adolescents ages 10 17 . ( 2.5 )",
    "warningsAndPrecautions": "16.1 supplied 10 mg white white coloured , round shaped , biconvex , film coated tablets debossed ‘ cl 42 ’ one side plain side . ndc 72162-2368-0 : 1000 tablets bottle 16.2 storage handlingstore olanzapine tablets , usp controlled room temperature , 20° 25°c ( 68° 77°f ) [ usp ] . usp defines controlled room temperature temperature maintained thermostatically encompasses usual customary working environment 20° 25°c ( 68° 77°f ) ; results mean kinetic temperature calculated 25°c ; allows excursions 15° 30°c ( 59° 86°f ) experienced pharmacies , hospitals , warehouses . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "• none olanzapine tablets monotherapy . • using olanzapine fluoxetine combination , also refer section package insert symbyax . • information lithium valproate , refer section package inserts products .",
    "indications_original": "Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: ·   Treatment of schizophrenia. ( 1.1 ) ·   Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) ·   Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) ·   Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) ·   Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) ·   Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) ·   Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) ·   Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) ·   Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As Olanzapine and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. ( 1.5 ) • Efficacy was established with Symbyax (olanzapine and fluoxetine in combination); refer to the product label for Symbyax. Treatment of treatment resistant depression. ( 1.6 ) • Efficacy was established with Symbyax (olanzapine and fluoxetine in combination) in adults; refer to the product label for Symbyax",
    "contraindications_original": "Schizophrenia in adults ( 2.1 ) Oral: Start at 5‑10 mg once daily; Target: 10 mg/day within several days Schizophrenia in adolescents ( 2.1 ) Oral: Start at 2.5‑5 mg once daily; Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) in adults ( 2.2 ) Oral: Start at 10 or 15 mg once daily Bipolar I Disorder (manic or mixed episodes) in adolescents ( 2.2 ) Oral:  Start at 2.5-5 mg once daily; Target: 10 mg/day Bipolar I Disorder (manic or mixed episodes) with lithium or valproate in adults ( 2.2 ) Oral: Start at 10 mg once daily Depressive Episodes associated with Bipolar I Disorder in adults ( 2.5 ) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily Depressive Episodes associated with Bipolar I Disorder in children and adolescents ( 2.5 ) Oral in combination with fluoxetine: Start at 2.5 mg of oral olanzapine and 20 mg of fluoxetine once daily Treatment Resistant Depression in adults ( 2.6 ) Oral in combination with fluoxetine: Start at 5 mg of oral olanzapine and 20 mg of fluoxetine once daily • Lower starting dose recommended in debilitated or pharmacodynamically sensitive patients or patients with predisposition to hypotensive reactions, or with potential for slowed metabolism. ( 2.1 ) • Olanzapine may be given without regard to meals. ( 2.1 ) Olanzapine and Fluoxetine in Combination: • Dosage adjustments, if indicated, should be made with the individual components according to efficacy and tolerability. ( 2.5 , 2.6 ) • Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder or treatment resistant depression. ( 2.5 , 2.6 ) • Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in adults. ( 2.5 , 2.6 ) • Safety of co-administration of doses above 12 mg olanzapine with 50 mg fluoxetine has not been evaluated in children and adolescents ages 10 to 17. ( 2.5 )",
    "warningsAndPrecautions_original": "16.1 How Supplied\n                  10 mg are white to off white coloured, round shaped, biconvex, film coated tablets debossed ‘CL 42’ on one side and plain on other side.\n                  \n                     NDC 72162-2368-0: 1000 Tablets in a BOTTLE\n                  \n                  16.2 Storage and HandlingStore olanzapine tablets, USP at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "• None with olanzapine tablets monotherapy. • When using olanzapine and fluoxetine in combination, also refer to the Contraindications section of the package insert for Symbyax. • For specific information about the contraindications of lithium or valproate, refer to the Contraindications section of the package inserts for these other products."
}